Eukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination.
For further information, see www.eukarys.com.
Industry
Biotechnology, Scientific Research and Development Services, Services
HQ Location
4, Rue Pierre Fontaine
Évry, Ile-de-France 91000, FR
Keywords
mRNAC3P3 technologyRNA polymerasesCapping enzymesgeneticsgenomicsmolecular biologymessenger RNASynthetic gene therapyGene therapy